$13.92
N/A
Last update: Nov 10, 4:00 PM
Crescent Biopharma Inc
CBIONASDAQ
Crescent Biopharma rose 5.1% from $13.25 to $13.92, behind the S&P 500's +9.8%. Its worst day was May 1 (−19.2%), and its low came Feb 13 at $8.94.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Crescent Biopharma shares rose 14.3%, while the S&P 500 fell 0.5%.
+14.3% · S&P 500 −0.5%
Crescent Biopharma closed at its lowest level of the year, 32.5% below where the year started.
−3.1% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $-4.01 missed the $-2.58 estimate on $10.8M revenue (est. $12.5M).
−1.2% · S&P 500 −0.6%
Crescent Biopharma shares rose 14.6%, while the S&P 500 fell 1.8%.
+14.6% · S&P 500 −1.8%
Crescent Biopharma closed at its highest level of the year, 103.6% above where the year started.
+9.8% · S&P 500 +1.0%
EPS of $-0.70 beat the $-0.80 estimate on $1.0M revenue (est. $357,140.00).
+6.8% · S&P 500 +1.0%
Crescent Biopharma shares fell 13.8%, while the S&P 500 rose 0.1%.
−13.8% · S&P 500 +0.1%
EPS of $-0.74 missed the $-0.67 estimate on $0.00 revenue (est. $357,140.00).
+1.7% · S&P 500 +1.7%
Crescent Biopharma shares fell 13.7%, while the S&P 500 fell 0.7%.
−13.7% · S&P 500 −0.7%
Where it ended: a close of $13.92 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.60, revenue est. $357,140.00).
Nothing in the past 12 months.
All CBIO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CBIO and SPY from Benzinga historical bars. Not investment advice.
